TLR4 and metabolic dysfunction-associated steatotic liver disease: Myricetin supplementation has been shown to regulate the gut microbiota in rats with non-alcoholic fatty liver disease (NAFLD) by increasing the abundance of butyric acid-producing bacteria and decreasing plasma LPS that activates TLR4, leading to decreased inflammation [23].